Mochida Pharmaceutical‘s patent involves a self-emulsifying composition for encapsulation in a capsule, containing ?3 polyunsaturated fatty acids, water, emulsifiers, and lecithin. The preparation aims to achieve specific plasma EPA concentrations in humans post-administration, offering improved absorbability and stability for food and pharmaceutical applications. GlobalData’s report on Mochida Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Mochida Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Mochida Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Mochida Pharmaceutical's grant share as of February 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11911480B2) discloses a self-emulsifying preparation encapsulated in a capsule, containing a specific composition. The composition includes eicosapentaenoic acid (EPA) or its pharmaceutically acceptable salts and esters, water, a nonionic surfactant emulsifier, polyhydric alcohol, ethanol, and lecithin. Upon administration to humans, the preparation must meet certain criteria related to plasma EPA concentration, Tmax, and blood EPA concentration. The amount of EPA in the composition ranges from 50 to 95% by weight, with a total composition weight of 1000 mg to 10000 mg when administered.

Furthermore, the patent details variations in the self-emulsifying preparation, such as the use of an ethyl ester of EPA, specific nonionic surfactants like polyoxyethylene sorbitan fatty acid ester or polyoxyethylene castor oil, and additional criteria for plasma EPA concentration under fasting conditions. The composition aims to achieve specific plasma EPA concentrations and areas under the curve within a defined time frame after administration. These claims highlight the precise formulation requirements and performance expectations for the self-emulsifying composition to ensure optimal bioavailability and efficacy in delivering EPA to the human body.

To know more about GlobalData’s detailed insights on Mochida Pharmaceutical, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies